| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.64 | 0.007 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.14 | 0.008 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.008 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.009 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |